Intravenous Ibandronate (Boniva)
Ibandronate (Boniva - Roche) is the first bisphosphonate approved by the FDA for intravenous (IV) treatment of osteoporosis in postmenopausal women. It is given as a bolus injection once every 3 months. Ibandronate is also available as an oral once-a-month 150-mg tablet and as a daily 2.5-mg tablet....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Intravenous Ibandronate (Boniva)
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1241
Article Code: 1241c
Date: August 14, 2006
Volume: 48
Pages: 68-69
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1241
Article Code: 1241c
Date: August 14, 2006
Volume: 48
Pages: 68-69
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)